Get informed when a big investor buys or sells
+ FollowUndervalued by 19.6% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $4.04 Billion |
|---|---|
| Enterprise Value | $-41,547,918,368.00 |
| Annual dividend | $0.23 |
| Dividend yield | 1.97% |
| Earnings per Share | $121.43 |
| Beta | 0.24 |
| Outstanding Shares | 321,344,079 |
| P/E Ratio | 16.91 |
|---|---|
| PEG | 1819.88 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | 2.05 |
| Enterprise Value to EBIT | 12.89 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.12 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 0.00%0% |
|---|---|
| Total Invested | $325▼ 19.35% |
| Investors Holding | 10% |
Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research, development, manufacturing, and marketing of both pharmaceutical products and medical devices. The company's primary focus lies in ophthalmic solutions, addr...